DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 Mar, 2024, 16:01 ET – Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis – Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif., March 27, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December […]

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More »

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

20 Mar, 2024, 16:30 ET CUPERTINO, Calif., March 20, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update Read More »

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

04 Mar, 2024, 07:00 ET Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ — DURECT

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada Read More »

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07 Feb, 2024, 18:48 ET CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024. Presentation details are as follows: Date and Time:     

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Read More »

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

13 Nov, 2023, 16:05 ET –  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET –  Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif., Nov. 13, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update Read More »

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

09 Nov, 2023, 16:30 ET CUPERTINO, Calif., Nov. 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update Read More »

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

07 Nov, 2023, 16:01 ET Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC) Numerical improvement in primary endpoint of mortality or transplant

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality Read More »

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

 07 Sep, 2023, 07:00 ET  Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif., Sept. 7, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Read More »

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

 31 Aug, 2023, 16:30 ET  CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, will present in the following September 2023 conferences.  H.C.

DURECT Corporation Announces Presentations in Upcoming Investor Conferences Read More »

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

 09 Aug, 2023, 16:05 ET  –    Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET –    Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif., Aug. 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update Read More »

Scroll to Top